|Send to printer »|
Corporate Profile : May 1, 2013 ( )
Twin Effort Hones In on Membrane Proteins
Calixar and Synthelis Join Forces to Offer Clients a Range of Services!--h2>
Two French companies are pooling their talents to offer comprehensive services for the isolation and production of target membrane proteins. Company officials say the two organizations work so closely together that they virtually emulate the activities of a single larger firm.
Lyon-based Calixar specializes in upstream processes ranging from identification to crystallization of target membrane proteins. Synthelis, which is located in Grenoble, uses its expertise in multi-expression systems and functional characterization to produce target proteins. The combined services provide clients with intact membrane proteins that maintain their native conformations. This is designed to improve drug discovery, antibody development, vaccine formulation, and structure-based research.
Both companies started in January 2011 and quickly formed an alliance after meeting in Paris at a national awards ceremony that honored innovative startup firms. Their mutual interest and complementary skills in membrane proteins led to the collaboration. “Our customers benefit from this critical mass of know-how and technology,” says Emmanuel Dejean, Ph.D., co-founder and CEO of Calixar.
Membrane proteins make up 20–30% of all cellular proteins, and 70% of them are possible pharmaceutical targets. They could help in the search for therapies for cancer and infectious, neurodegenerative, metabolic, genetic, and other diseases. However, only about 2% of membrane proteins have been structurally characterized, greatly limiting structure-based drug design, according to Dr. Dejean.
Pierre Falson, Ph.D., and Dr. Dejean started Calixar. Dr. Falson invented and patented a technology for extracting membrane proteins at the Centre National de la Recherche Scientifique in Lyon. Calixar holds an exclusive license that covers a series of reagents that extract membrane proteins and crystallizes them without causing denaturation.
“Our principal goal is to avoid denaturation. We use specific patented reagents to carry out the extraction and purification of proteins,” notes Dr. Dejean. A series of 16 reagents has been developed to work in combination with commercial products to optimize the outcome. Some additional “know-how” is also required, he says.
At the core of the technology are macrocyclic molecules called calixarenes, which are detergents with chemical structures that resemble a chalice. The Latin word for chalice is calix, the source of the company’s name.
The reagents work through hydrophobic interactions and a network of salt bridges within the cytosol of membrane proteins. They act as mild surfactants to remove membrane proteins, while preserving the protein’s function and structure for crystallization.
Standard methods for crystallizing membrane proteins rely on detergents to extract them from the cell’s lipid bilayer. These methods, however, damage proteins and cause unfolding and loss of activity, according to Dr. Dejean. “Drugs based on a denatured protein perform inefficiently or have side effects,” he points out.
Cell-Free Expression System
Bruno Tillier and Jean-Luc Lenormand, Ph.D., started Synthelis. Dr. Lenormand invented and patented a cell-free expression system that produces functional membrane proteins in a proteoliposome form in his laboratory at Joseph Fourier University in Grenoble. The system was adapted to produce difficult-to-express proteins as targets for drug discovery, vaccine development, and protein therapy.
Synthelis specializes in making fully functional membrane proteins, including ion channels, porins, and G-protein coupled receptors from humans, animals, bacteria, viruses, and plants. The company’s single-stage, “open system” production platform uses key protein-making cellular components, rather than cultured whole cells, explains Dr. Lenormand. In whole-cell methods, the over-expressed target proteins aggregate in inclusion bodies that must be broken apart to obtain the protein. This disruption damages the natural protein structure and consequently alters its activity.
Because Synthelis’ cell-free system is not surrounded by a cell membrane, other agents can be readily added during protein synthesis. Synthelis adds liposomes, a key ingredient that maintains the natural state of proteins. The company has expressed more than 50 proteins for its partners.
Clients send Synthelis the gene sequence or any genetic material from a membrane protein of interest. Synthelis carries out a feasibility study to test the expression conditions and optimize protein activity. They also can start the scaleup of a protein and estimate the time needed to generate a required amount of product. Up to milligram amounts of membrane proteins can be manufactured in a few months.
Tillier says the alliance of Calixar and Synthelis strengthens the business and technical clout of each as well as their visibility. “It also improves our ability to innovate to find answers to complex sets of problems,” he adds. Although most of their clients are European pharmas and biotechs, both firms want to work with drug discovery companies in the U.S. and elsewhere.
Location: c/o IBCP 7 Passage du Vercors
Phone: +33 4 37 65 29 39
Principal: Emmanuel Dejean, Ph.D., co-founder, CEO
Number of Employees: 11
Focus: Calixar specializes in the upstream isolation, purification, and crystallization of native membrane proteins.
Location: 5 Avenue du Grand Sablon
Phone: +33 4 76 54 95 37
Number of Employees: 9
Focus: Synthelis develops, produces, and characterizes fully functional membrane proteins using a cell-free technology.
© 2013 Genetic Engineering & Biotechnology News, All Rights Reserved